Sapience Therapeutics is a biotechnology company focused on developing peptide inhibitors to target intracellular protein-protein interactions in cancer cells. The company's discovery platform generates drug candidates that specifically address transcriptional regulation of oncogenic and immune modulatory proteins. Their lead candidate, ST101, is designed to induce cell death in solid tumors such as breast cancer, melanoma, prostate cancer, and glioblastoma, as well as in hematologic malignancies. Sapience Therapeutics operates in the oncology market, serving patients with unmet medical needs. The company generates revenue through the development and potential commercialization of its therapeutic candidates.

Keywords: peptide inhibitors, cancer treatment, protein interactions, oncology, drug discovery, solid tumors, immune modulation, ST101, biotechnology, therapeutic development.